I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC 2018

World Conference on Lung Cancer 2018

At the IASLC World Conference on Lung Cancer meeting, Boehringer Ingelheim hosted a symposium and a number publications related to our products were presented to highlight our advances in the treatment of lung cancer.

Symposium: Overcoming Challenges In Thoracic Malignancies: Expert Insights

An international faculty of experts discussed clinical considerations for sequencing EGFR TKIs, for preventing and managing brain metastases in patients with EGFR mutation-positive NSCLC, and for maximising the potential of TKIs for SqCC of the lung.

 

Please see below for symposium presentation downloads.

Noemi Reguart, MD, PhD

Clinical considerations in EGFR mutation-positive NSCLC: the challenge of preventing and managing brain metastases

Presenter(s): Noemi Reguart, MD, PhD
Barbara Melosky, MD, FRCP(C)

Clinical considerations in EGFR mutation–positive NSCLC: does treatment sequence matter?

Presenter(s): Barbara Melosky, MD, FRCP(C)
David R. Gandara, MD

Maximising the clinical potential of TKIs for patients with squamous NSCLC

Presenter(s): David R. Gandara, MD
Publications

Please see downloadable versions below.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Monday 24th September 2018
A Phase IIIb trial of afatinib* in EGFRm+ NSCLC: analyses of outcomes in patients with brain metastases or dose reductions
Author(s): Yi-Long Wu et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.01-98
Named patient use program for afatinib in advanced NSCLC with progression on prior therapy: experience from Asian centers
Author(s): Gee-Chen Chang et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P0.01-11
Impact of afatinib dosing on safety and efficacy real-world in patients with EGFR mutation-positive advanced NSCLC (RealGiDo)
Author(s): Balazs Halmos et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.01-28
There are no publications which meet your criteria on this date
Tuesday 25th September
Nintedanib** + pemetrexed/cisplatin in patients with unresectable MPM: Phase III results from the LUME-Meso trial
Author(s): Giorgio Scagliotti et al.
Oral Presentation
Tumour Type(s): MPM
Presentation Number: PL02.09
There are no publications which meet your criteria on this date
Wednesday 26th September
Oncologist Treatment Considerations and Selection in EFGRM+ NSCLC
Author(s): Thomas Wehler et al.
Poster Presentation
Tumour Type(s): NSCLC, CRC
Presentation Number: P3.01-108
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 

Last updated: September 2018